ĐẶC ĐIỂM LÂM SÀNG, XÉT NGHIỆM VÀ KẾT QUẢ ĐIỀU TRỊ VIÊM PHỔI DO MYCOPLASMA PNEUMONIAE Ở TRẺ EM

Abstract

Objective: To describe the clinical and laboratory features of children with M. pneumoniae at the National Children's Hospital from September 1, 2020 to August 30, 2022, and to describe the treatment outcomes in these patients. Subjects: 165 children diagnosed with pneumonia caused by M. pneumoniae. Methods: A cross-sectional study. Results: The mean age of children with M. pneumoniae was 4.08 ± 2.11 years, of which females 93 (56.4%), males 72 (43.6%) with a male/female ratio of 1.28. The disease occurs everytime in a year. Main clinical symptoms: cough 143/165 (92.1%), fever 99/165 (60%), crackles on lung auscultation 104/165 (63%), wheezing rales 65/165 (39.4%). Investigations: CBC had leukocytosis 127/165 (77%) and elevated serum CRP 81/165 (49.1%). 128/165 (77.6%) children were treated with Macrolide, the average hospital stay was 10.2 ± 7.4 days, resulting in 157/165 (95.2%) children cured and in remission after the treatment, and no deaths were recorded. Conclusion: The disease is not limited by seasonal variations and can affect children in any month. Common clinical symptoms are cough and fever. A common physical symptom is rales in the lungs. Regarding investigations, the majority of children with pneumonia caused by M. pneumoniae have leukocytosis in CBC. Macrolides are common antibiotics used in treatment. The cure rate is high, with no deaths.